Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZE trial of mitapivat in non-transfusion-dependent alpha- or beta-thalassemia
NL-OMON59353Phase 3Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alpha thalassemia and beta thalassemia comparing Mitapivat with Placebo (2 arms). Primary endpoint: Hemoglobin response. Started Jul 2024; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
alpha thalassemiabeta thalassemia
Beyond the preview
Go deeper on NL-OMON59353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59353.